Potentially Malignant Disorders
On this page
Direct answer
In 2005 the World Health Organization retired "premalignant lesion and condition" in favour of potentially malignant disorders, an umbrella that admits a simple truth: most of these mucosal states never transform, but no clinician can say which ones will. Under the umbrella sit leukoplakia (the commonest), erythroplakia (the most dangerous, with severe dysplasia or carcinoma in situ found in the large majority at biopsy), oral submucous fibrosis (India's areca-driven epidemic), lichen planus, actinic cheilitis and the inherited and deficiency-linked syndromes. Management runs on three verbs — stop the habit, biopsy the lesion, watch the patient — because transformation risk lives in morphology, site, histology and behaviour, and it is reassessed at every review.
What you must remember
- The 2005 WHO terminology shift — from lesion and condition to "potentially malignant disorders" — is itself examined; the phrase implies a family of states with variable, unpredictable transformation risk.
- Leukoplakia: diagnosis of exclusion; risk factors tobacco in every form (including gutkha, khaini and paan with tobacco), areca nut and alcohol; transformation affects a small minority overall, climbing steeply for non-homogenous morphology, floor-of-mouth and ventral tongue sites, higher dysplasia grades and continued habits.
- Erythroplakia: the velvet-red patch that cannot be explained otherwise; histology shows severe dysplasia, carcinoma in situ or invasive carcinoma in commonly quoted figures around 80-90 per cent — the highest-risk disorder in the group, treated by excision, not observation.
- Oral submucous fibrosis: arecoline-driven fibroblast stimulation and collagen deposition produces blanching, marble-like mucosa, burning dysaesthesia, palpable fibrotic bands and progressive trismus; it is independently potentially malignant, with transformation commonly quoted in the mid single-digit percentages.
- Other members to name: lichen planus (erosive forms carry a small contested risk), actinic cheilitis of the lower lip in outdoor workers, dyskeratosis congenita, xeroderma pigmentosum, Fanconi anaemia, sideropenic dysphagia (Plummer-Vinson syndrome with its oesophageal carcinoma risk), chronic hyperplastic candidosis, and reverse-smoker's keratosis.
- Management sequence: habit cessation first, incisional biopsy for histological grading (mild, moderate, severe dysplasia), excision or laser ablation for significant dysplasia and erythroplakia, and lifelong surveillance at intervals of three to six months.
- Indian screening evidence: oral visual examination of high-risk users reduced oral cancer mortality in the Kerala cluster-randomised trial.
- Grading trismus in oral submucous fibrosis by interincisal opening guides treatment: physiotherapy, intralesional corticosteroids with hyaluronidase, lycopene and antioxidant support in early disease; surgical release with flap reconstruction in advanced disease.
Managing an areca user with a stiff mouth
A 42-year-old presents with two years of burning on spicy food and progressive difficulty opening; he has chewed gutkha fifteen times daily for sixteen years. The mucosa is blanched and marble-like over both cheeks and the soft palate, palpable fibrotic bands run in the buccal mucosa, and the interincisal opening is 26 mm. Along the right buccal mucosa, a speckled white-and-red patch sits within the fibrotic field. Diagnosis: oral submucous fibrosis with a coexistent non-homogenous leukoplakia — two potentially malignant disorders in one mouth. Plan in order: structured gutkha cessation (the single intervention that changes every downstream risk), incisional biopsy of the speckled area for dysplasia grading, trismus staging and physiotherapy with an exerciser, and intralesional therapy with corticosteroid and hyaluronidase courses. If histology reports moderate or severe dysplasia, the leukoplakia is excised or laser-ablated. Surveillance is fixed at three-to-six-month intervals with photography and measurement, and the patient is told that any new ulcer, induration or colour change brings him straight back — surveillance, not reassurance, is the treatment.
Where students slip
Terminology currency is the first filter: candidates still answering in "premalignant lesions and conditions" have not read the 2005 WHO shift and its rationale — that most lesions never transform, so "potentially" carries the epistemology. The second is risk arithmetic delivered flat: a single transformation percentage for leukoplakia, without stratifying by non-homogenous morphology, site and dysplasia, answers a question the examiner did not ask. The third is erythroplakia complacency: any answer that includes observation for a velvet-red patch fails — the biopsy finding distribution makes it a surgical diagnosis. Finally, in oral submucous fibrosis, candidates who recite surgery first have reversed the ladder: cessation, physiotherapy and intralesional medical therapy precede release procedures.
Frequently asked questions
Why did the WHO replace premalignant lesions and conditions?
The 2005 term "potentially malignant disorders" reflects variable, largely unpredictable transformation risk — most never become cancer, and the family includes conditions beyond lesions.
List the principal potentially malignant disorders.
Leukoplakia, erythroplakia, oral submucous fibrosis, erosive lichen planus, actinic cheilitis, chronic hyperplastic candidosis, sideropenic dysphagia and inherited syndromes.
Why is erythroplakia the highest-risk disorder?
Biopsy reveals severe dysplasia, carcinoma in situ or invasive carcinoma in roughly 80-90 per cent of cases.
How is early oral submucous fibrosis managed?
Areca and tobacco cessation, physiotherapy, intralesional corticosteroids with hyaluronidase, nutritional support — surgery reserved for refractory advanced trismus.
Which factors raise leukoplakia's transformation risk?
Non-homogenous morphology, floor-of-mouth and ventral tongue sites, dysplasia grade, persistence after cessation, and older age.
What surveillance follows diagnosis?
Review every three to six months for life, with immediate biopsy of any change.